Keene & Associates’s Pfizer PFE Stock Holding History

Keene & Associates’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$2.52M	Sell	95,073 -16,929	-15%	-$459K	2.03%	25
2024 Q3	$3.24M	Buy	112,002 +315	+0.3%	+$9.19K	2.46%	21
2024 Q2	$3.13M	Sell	111,687 -534	-0.5%	-$14.7K	2.55%	23
2024 Q1	$3.11M	Buy	112,221 +48,106	+75%	+$1.33M	2.33%	28
2023 Q4	$1.85M	Sell	64,115 -3,848	-6%	-$116K	1.53%	29
2023 Q3	$2.25M	Buy	67,963 +2,571	+4%	+$90.9K	1.81%	29
2023 Q2	$2.4M	Buy	65,392 +1,900	+3%	+$74K	1.86%	31
2023 Q1	$2.59M	Sell	63,492 -201	-0.3%	-$8.68K	2.01%	31
2022 Q4	$3.26M	Buy	63,693 +1,613	+3%	+$77.3K	2.91%	12
2022 Q3	$2.72M	Sell	62,080 -2,850	-4%	-$138K	2.5%	18
2022 Q2	$3.4M	Buy	64,930 +125	+0.2%	+$6.37K	3.19%	5
2022 Q1	$3.35M	Sell	64,805 -673	-1%	-$34.9K	2.74%	17
2021 Q4	$3.87M	Buy	+65,478	New	+$3.24M	3.34%	2

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Keene & Associates's PFE Position: Q4 2024 in Review

Keene & Associates reduced its Pfizer (PFE) stake by 15% in Q4 2024, selling an estimated $459K and leaving 95,073 shares worth $2.52M. The position accounts for 2.03% of the portfolio, ranked #25.

Keene & Associates first reported a position in PFE in Q4 2021 and has held it in 13 quarters since. The position peaked at $3.87M in Q4 2021. 2,995 funds tracked by Wall St. Rank hold PFE as of Q4 2024.

Keene & Associates held 95,073 shares of Pfizer worth $2.52M as of Q4 2024.
Keene & Associates sold 16,929 Pfizer shares in Q4 2024, an estimated $459K.
Pfizer made up 2.03% of Keene & Associates's portfolio in Q4 2024, its #25 holding.
Keene & Associates first reported a position in Pfizer in Q4 2021 and has held it in 13 quarters since.
Keene & Associates's Pfizer position peaked at $3.87M in Q4 2021.
2,995 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.

Based on Keene & Associates's 13F filing for Q4 2024, filed 3 Feb 2025.